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Abstract
Neurofibromatosis 2 (NF2) is a rare tumor suppressor syndrome that manifests with multiple
schwannomas and meningiomas. There are no effective drug therapies for these benign
tumors and conventional therapies have limited efficacy. Various model systems have been
created and several drug targets have been implicated in NF2-driven tumorigenesis based
on known effects of the absence of merlin, the product of the NF2 gene. We tested priority
compounds based on known biology with traditional dose-concentration studies in meningi-
oma and schwann cell systems. Concurrently, we studied functional kinome and gene
expression in these cells pre- and post-treatment to determine merlin deficient molecular
phenotypes. Cell viability results showed that three agents (GSK2126458, Panobinostat,
CUDC-907) had the greatest activity across schwannoma and meningioma cell systems,
but merlin status did not significantly influence response. In vivo, drug effect was tumor spe-
cific with meningioma, but not schwannoma, showing response to GSK2126458 and Pano-
binostat. In culture, changes in both the transcriptome and kinome in response to treatment
clustered predominantly based on tumor type. However, there were differences in both
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gene expression and functional kinome at baseline between meningioma and schwannoma
cell systems that may form the basis for future selective therapies. This work has created an
openly accessible resource (www.synapse.org/SynodosNF2) of fully characterized isogenic
schwannoma and meningioma cell systems as well as a rich data source of kinome and
transcriptome data from these assay systems before and after treatment that enables single
and combination drug discovery based on molecular phenotype.
Introduction
Neurofibromatosis 2 (NF2) is a rare neurogenetic disorder (affecting roughly 1 in 33,000 peo-
ple around the world) that is characterized by multiple schwannomas and meningiomas [1].
These are benign histologically, but their multiplicity, involving multiple cranial nerves, spinal
nerve roots and peripheral nerves in people with NF2 results in severe cumulative morbidity
and ultimately, death. Although bilateral vestibular schwannomas are pathognomonic for
NF2, meningiomas are the second most common tumor type in NF2 and their presence is
associated with increased mortality [2]. Importantly, meningiomas are the most common
brain tumor worldwide and many sporadic meningiomas have somatic NF2 mutations [3,4].
In most non-NF2 patients, meningiomas and schwannomas are effectively treated with sur-
gery or radiation therapy. In the setting of NF2, surgery and radiation therapy are associated
with reduced efficacy and increased toxicity and there are no effective drug therapies for these
tumors [5–7]. Hence, effective treatments for NF2-associated schwannomas and meningiomas
are a major unmet medical need for both the broad population with sporadic forms of these
tumors as well as for people with the rare syndrome of NF2.
A conventional approach to developing drug therapies for tumors is for individual laborato-
ries to test new or repurposed drugs in various in vitro and in vivo assay model systems based
on hypotheses about tumor pathogenesis [8]. NF2-associated meningiomas and schwannomas
result from a classic tumor suppressor gene mechanism involving inheritance of an inactivating
mutation in the NF2 gene on chromosome 22q, followed by somatic inactivation of the remain-
ing copy of NF2 (either by mutation or loss of a large section of the surrounding chromosome).
Merlin is the NF2 tumor suppressor protein, and loss of merlin function results in dysregulation
of multiple aspects of cellular behavior [9]. This knowledge has supported the generation of
NF2/Nf2 mutant in vivo and in vitro model systems [10–20]. These are powerful tools to under-
stand the molecular basis of tumorigenesis and to assess drug effects in a system reflecting mer-
lin loss. However, there are relatively few assay systems available and each has advantages and
limitations to consider when making a commitment to clinical translation. Additional system-
atic limitations in developing effective therapies for NF2 mutant tumors include: variable met-
rics of efficacy applied across individual laboratories and systems, limited focus on drug targets
implicated by merlin loss, and histologically specific drug assessment (meningioma versus
schwannoma) rather than assessment of the effect of the underlying NF2 mutation on drug
response. To address these limitations a multi-disciplinary team created a panel of in vitro assay
systems (representing meningioma and schwannoma, merlin wildtype and merlin-deficient,
and human and murine cells) to perform traditional drug screening studies in a systematic fash-
ion with an initial set of drugs chosen for their potential relevance to NF2 biology.
Simultaneously, we performed an integrated analysis of transcriptome and kinome data
across these cell culture systems at baseline and after treatment to discover tumor, species and
merlin specific therapeutic targets, identify differential responses to treatment, and potentially
Systems based drug discovery for NF2
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identify mechanisms of acquired resistance. The goal was to compare drug efficacy readouts
with traditional drug discovery approaches versus systems biology approaches via systematic
drug assays in fully characterized isogenic pairs of schwannoma and meningioma model sys-
tems (Fig 1). The ultimate goal of this work was to create an assay system and data resource for
the scientific community, with the long term goal of improving the pipeline that will identify
biologically relevant therapies to be advanced for clinical development to help people with
NF2 and NF2 driven tumors.
Results
Development of disease-specific cell lines for drug screening
We assembled a panel of tumor-relevant cells (Schwann cells for schwannoma and arachnoidal
cells for meningioma) confirmed to have suppressed or inactivated merlin and, whenever pos-
sible, their merlin-wildtype control (Table 1).
To represent the biology of meningiomas we assembled a primary screening cohort of 12
human cell lines, either merlin-wildtype or merlin-null. These included 5 isogenic clonally-
derived arachnoidal cell (AC-CRISPR) lines [11], of which two are merlin-wildtype controls
(Syn1 and Syn2) and three are merlin-deficient lines generated by CRISPR/Cas9 NF2 inactiva-
tion (Syn3, Syn4, and Syn5), along with the immortalized merlin-deficient benign meningi-
oma (MN) line Ben-Men-1 (Syn6) [12], as well as six patient-derived primary merlin-deficient
MN lines (Syn7-Syn12). Similar growth rates were observed among the isogenic clonally-
derived AC-CRISPR lines (Syn1-Syn5) and Ben-Men-1 (Syn6) line. Likewise, all chosen pri-
mary MN lines (Syn7-12) exhibited comparable growth rates.
To represent the biology of schwannoma formation, we employed a matched pair of
human fetal Schwann cell (SC) lines, (HS11, wild-type) and (HS01, NF2-shRNA suppressed
with ~3% merlin protein expression by Western blotting and ~7% RNA expression by RNA
sequencing versus wild-type) as well as a series of four mouse merlin-wildtype and -deficient
SC and a merlin-deficient schwannoma lineS [13,14] All control AC and SC lines expressed a
merlin band at ~70 kDa by Western blot, whereas human and mouse cell lines with NF2 or
Nf2 inactivation, respectively, failed to exhibit merlin protein (S1 Fig).
In vitro meningioma and schwannoma cell culture screening with targeted
compounds
Merlin is a ubiquitous protein that has both intracellular and extracellular effects [9,21,22].
Loss of functional merlin contributes to activation of multiple oncogenic pathways including
Fig 1. Schematic diagram for drug testing with mechanistically based candidate drugs in a traditional in vitro to
in vivo pipeline and simultaneous integrated transcriptome and kinome analysis of cells and murine tumors.
https://doi.org/10.1371/journal.pone.0197350.g001
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Ras, Rac, PI3K and mTOR signaling pathways [11,14–16,23,24]. In addition, merlin deficiency
has been linked to increased expression of several growth factor receptors including PDGFR,
the EGFR family, and possibly (via Tie2) VEGFR expression [13,21,25–28].
Based on what is known about the function of merlin pre-clinically and the performance
of various agents in prior preclinical and clinical evaluations, we assembled a panel of 19
drugs for initial testing in the cell culture panel that met the following requirements: (1)
biological activity in clinical trials in NF2 patients, (2) activity against targets in key path-
ways regulated by merlin, (3) FDA-approved or in the late stages of clinical development
(Table 2).
All 19 compounds were assessed in AC/MN and SC/schwannoma lines simultaneously.
Dose response curves (DRCs) were generated for all meningioma-relevant (Syn1–Syn12) and
schwannoma-relevant (HS01, HS11, MS01-MS12) cell lines using the CellTiter-Glo or CellTi-
ter-Fluor viability assay (Promega), respectively. For AC/MN cells, there were two stages of
screening. In the first stage, CellTiter-Glo was assessed at 72 hours of treatment using 5 dilu-
tion points (5-fold serial dilutions) of each drug, ranging from 0.04 μM to 25 μM. Based upon
DRCs generated for each cell line and compound, 8 of the 19 compounds were eliminated
due to minimal or no effect, even at the highest concentrations. For the remaining 11 com-
pounds, drug treatment was expanded to a second stage. In the second stage, immortalized
AC-CRISPR and Ben-Men-1 lines (Syn1-Syn6) as well as three primary MN lines (Syn7,
Syn10, and Syn12) were evaluated by generating DRCs using 10 dilution points (5-fold serial
dilutions) of each drug ranging from 12.8 pM to 25 μM (Fig 2A and S2A Fig). Four drugs
including Panobinostat, GSK2126458, CUDC-907 and Bortezomib revealed an IG50 < 250
nM with a maximum response > 50% inhibition in all cell lines tested (Fig 2A and 2D). Of the
remaining seven drugs, three (AR42, AZD2014 and GDC0980) showed an IG50< 2 μM in all
lines tested and four (Axitinib, Ganetespib, GDC0941 and Vorinostat) showed IG50 > 3 μM
or no response in the primary MN lines (S1 Table). Some drugs, specifically CUDC907 in the
Table 1. Meningioma, schwannoma, arachnoidal, and Schwann cell lines used for Synodos drug screens.
Cell Line Organism Type Grade Merlin Status
Syn1 Human Arachnoid cells (NF2+ CRISPR), isogenic n/a Wildtype
Syn2 Human Arachnoid cells (NF2+ CRISPR), isogenic n/a Wildtype
Syn3 Human Arachnoid cells (NF2- CRISPR), isogenic n/a Deficient
Syn4 Human Arachnoid cells (NF2- CRISPR), isogenic n/a Deficient
Syn5 Human Arachnoid cells (NF2- CRISPR), isogenic n/a Deficient
Syn6 Human BenMen1, immortalized meningioma n/a Deficient
Syn7 Human primary meningioma cell line I Deficient
Syn8 Human primary meningioma cell line I Deficient
Syn9 Human primary meningioma cell line I Deficient
Syn10 Human primary meningioma cell line I Deficient
Syn11 Human primary meningioma cell line II Deficient
Syn12 Human primary meningioma cell line II Deficient
HS01 Human Schwann cell NF2 shRNA 45 n/a Deficient
HS11 Human Fetal Schwann cell n/a Wildtype
MS01 Mouse Schwann cell Nf2ex2-/- n/a Deficient
MS02 Mouse schwannoma cell Nf2ex2-/- n/a Deficient
MS03 Mouse Schwann cell Nf2ex2-/- n/a Deficient
MS11 Mouse Schwann cell n/a Wildtype
MS12 Mouse mouse Schwann cell Nf2fl2/fl2 n/a Wildtype
https://doi.org/10.1371/journal.pone.0197350.t001
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human and mouse SC lines, as well as GSK2126458 in the mouse SC cell lines, did not reach
100% viability, indicating that these molecules have an effect at and possibly below the lowest
tested drug concentration.
For the human SC panel, cell viability was assessed with CellTiter-Fluor at 48 hours with
increasing concentrations at half-log concentrations, ranging from 0.001 μM to 10 μM. Five
drugs, including Panobinostat, GSK2126458, CUDC-907, Bortezomib and Ganetespib,
revealed IG50 <500 nM with a maximum response > 50% inhibition in merlin-deficient
HS01 (Fig 2B and 2E, S2B Fig). All other drugs showed IG50> 2 μM or not determined (n.d.;
maximum response <50%) (S2B Fig and S2 Table). Mouse SC lines treated with Panobinostat,
GSK2126458, CUDC-907 or Bortezomib revealed IG50 of 1 μM with a maximum
response > 55% inhibition in all merlin-deficient cell lines tested (MS01, MS02 and MS03)
(Fig 2C and 2E, S2 Table). All other drugs tested showed variable IG50 ranging from 2 nM
to> 5 μM or could not be determined in merlin-deficient mouse SC or schwannoma lines due
to DRC that could not be fitted (S3 Fig and S2 Table).
Comprehensive evaluation of the compounds’ performance across both AC/MN and SC/
schwannoma assay systems in vitro with the goal of selecting drugs that had the highest likeli-
hood of efficacy against both tumor types in vivo resulted in three compounds being selected
to be advanced to in vivo testing: CUDC-907 (dual PI3K/HDAC inhibitor), Panobinostat
(HDAC inhibitor), and GSK2126458 (dual PI3K/mTOR inhibitor).
Table 2. FDA approved or late–stage drugs selected for cell culture screening.
Compound Targetsa Inclusion Criteriab
LY2157299 TGF-beta/Smad 2,3[29]
Ganetespib (STA-9090) HSP (e.g HSP90) 2,3[30]
Panobinostat (LBH589) HDAC 2,3[27,31]
Vorinostat (SAHA, MK0683) Autophagy, HDAC 2,3[27,31]
AR-42 HDAC 1,2,3
[27,31]
Lapatinib (GW-572016) Ditosylate HER2, EGFR 1,2,3[24,32]
Axitinib VEGFR, PDGFR, c-Kit 1,2,3[21,25,28,33]
AZD2014 mTOR 1,2,3[11,15,23,34,35]
OSU-03012 (AR-12) PDK-1 2[21,36]
Perifosine (KRX-0401) AKT 2,3 [14,36–38]
Everolimus (RAD001) mTOR 1,2,3[11,15,23,34,35]
GSK2126458 (GSK458) PI3K, mTOR 2,3[15,36]
GDC-0980 (RG7422) PI3K, mTOR 2,3 [15,36]
CUDC-907 PI3K, HDAC 2,3 [13,16,36,39]
GDC-0941 PI3K 2,3[16,36]
Selumetinib (AZD6244) MEK 2,3[24]
Trametinib (GSK1120212) MEK 2,3[24]
Vismodegib (GDC-0449) Hedgehog/Smoothened 2,3[38,40,41]
Bortezomib (PS-341) Proteasome 2,3[42]
aTGF-beta, transforming growth factor beta; HSP, heat shock protein; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; EGFR, epidermal
growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; c-Kit, tyrosine-protein kinase Kit; mTOR,
mammalian target of rapamycin; PDK-1, pyruvate dehydrogenase kinase 1; AKT, protein kinase B; PI3K, phosphoinositide 3-kinase; MEK, MAPK/ERK kinase.
b(1) biological activity in clinical trials in NF2 patients, (2) activity against targets in a key pathway regulated by merlin, (3) FDA-approved or in the late stages of clinical
development.
https://doi.org/10.1371/journal.pone.0197350.t002
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Variables associated with drug response in meningioma and schwannoma
cell culture systems
We assessed the effects of tumor type, cell line species, and merlin status as covariates for drug
response via multiple linear regression (Fig 3; S3 Table), [43]. This method estimates the β
Fig 2. Treatment response of merlin-wildtype and merlin-deficient cells with compounds meeting efficacy
metrics. (A) 72-hour dose response curves (DRCs) were generated for the human meningioma-relevant cell panel
including all AC-CRISPR (blue), immortalized Ben-Men1 (Syn6, yellow), and 3 primary MN lines (red). (B) 48-hour
DRCs for human SC including merlin-deficient (red) and merlin-wildtype (WT, blue) lines are shown. (C) DRCs
generated for mouse SC/schwannoma-related lines including merlin-deficient (red) and merlin-wildtype (WT, blue)
are also shown. All DRCs are expressed as percent cell viability (cell viability %) relative to vehicle treatment. Drug
concentrations are expressed as log10 (μM) scale. (D) Dose-response metrics in AC, MN and (E) SC/schwannoma
lines of compounds meeting efficacy metrics.
https://doi.org/10.1371/journal.pone.0197350.g002
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coefficient (the slope of the relationship between variables) for each covariate as it pertains to
the dependent variable, and calculates the significance of the estimates by performing an F-test
(testing the null hypothesis the β coefficient is zero). Among these three covariates, tumor type
showed the greatest correlation with drug efficacy as measured by area under the curve (AUC)
of each drug’s dose response curves (Fig 3A). Under the conditions tested, cell line species
showed a moderate correlation with AUC, with mouse lines exhibiting slightly greater drug
sensitivity. Hierarchical clustering also showed schwannoma models to be consistently more
sensitive than meningioma models (Fig 3B). Conversely, merlin status did not significantly
affect drug sensitivity with this panel of drugs (Fig 3A and 3B).
Fig 3. Drug screening outcomes are largely independent of merlin status. (A) Estimated beta coefficients of different assay variables to differences in area
under the curve (AUC) as determined by multiple linear modeling. Multiple linear modeling indicates that unlike merlin status, tumor type and treatment with a
subset of drugs (CUDC-907, Bortezomib, Panobinostat, GSK2126458, Ganetespib, and Axitinib) are significantly associated with a reduction in cell viability as
measured by Simpson AUC. (B) Hierarchical clustering demonstrates similarity of response (Simpson AUC) of all cell lines to tested drugs. Only drugs common
to both cell types were included in the analysis. Based on the response of each cell line to the entire panel of drugs, the cell lines appear to cluster by cell type and
merlin status.
https://doi.org/10.1371/journal.pone.0197350.g003
Fig 4. Anti-tumor efficacies of GSK2126458, Panobinostat, and CUDC-907 in the quantifiable, orthotopic, merlin-deficient benign meningioma model.
Luciferase-expressing Ben-Men-1-LucB cells were stereotactically injected at the skull base, and mice with established tumors were randomized into three groups for
treatment by oral gavage as described in Methods. (A) One half of the first group of mice was treated with GSK2126458 and the other half fed the vehicle used for
drug formulation (n = 8 each). (B-C) Likewise, the second group of mice was treated with (B) Panobinostat or the vehicle, and the third group was fed CUDC-907
or (C) the formulating vehicle. Tumor growth was monitored by BLI and the relative bioluminescence signals emitted from tumors in mice were quantified and
denoted as the percentage of total flux after treatment relative to the total flux prior to treatment designated as one (100%). Shown are the data as mean ± standard
deviation.
https://doi.org/10.1371/journal.pone.0197350.g004
Systems based drug discovery for NF2
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In vivo testing of candidate compounds in a meningioma xenograft model
GSK2126458, Panobinostat, and CUDC-907 were evaluated in the orthotopic merlin-deficient
benign meningioma Ben-Men-1-LucB xenograft model [18]. The maximal tolerated doses in
this model were determined to be 2 mg/kg/day for GSK2126458 by oral gavage, 20 mg/kg
every other day for Panobinostat via intraperitoneal injection, and 25 mg/kg/day for CUDC-
907 by oral gavage. Following treatment, tumor growth was monitored by bioluminescence
imaging (BLI). Previously work showed that bioluminescence signal in luciferase-expressing
tumor xenografts correlates with the tumor size [27]. Mice had a reduction in tumor size
within one month of starting GSK2126458. Of note, at six to eight weeks of treatment there
was a gradual rebound in tumor-emitted bioluminescence, but even with this, GSK2126458
suppressed tumor growth by an average of ~56% relative to vehicle-treated tumors at four
months (Fig 4A). Meningioma xenografts treated with Panobinostat did not grow following
treatment, and the magnitude of growth suppression became more significant over time versus
vehicle-treated tumors which grew more than 400% (Fig 4B). CUDC-907 at 25 mg/kg/day
resulted in a trend of suppression of tumor growth compared with vehicle-treated controls
after ten weeks with an average reduction of 55% in tumor size after 14 weeks of treatment
(Fig 4C). Growth suppression via in tumor-emitted bioluminescence was corroborated by
immunohistochemical analysis (S1 Text).
In vivo testing of candidate compounds in a genetically-engineered mouse
schwannoma model
GSK2126458, Panobinostat, and CUDC-907 were evaluated in a genetically-engineered mouse
(GEM) model of NF2, PostnCre; Nf2floxflox, that develops schwannoma of the dorsal root gan-
glia (DRG) and cranial nerves [19]. Each drug was administered for a treatment period of 12
weeks. Tumor burden and hearing were assessed at the conclusion of treatment. Pharmacoki-
netic parameters, including tissue concentrations (Fig 5D), were observed to be similar to pre-
viously published results [44–46]. GSK2126458 was initially administered by daily oral gavage
at 3 mg/kg/day, but subsequently decreased to 1.5 mg/kg/day due to significant GI toxicity.
The reduced dose was well tolerated. Panobinostat was given via intraperitoneal injection at a
dose of 20 mg/kg 3x/week and was well tolerated. CUDC-907 was poorly tolerated, both at
oral doses of 100 mg/kg/day and 50 mg/kg/day pointing to differences with the meningioma
model (S2 Text). A dose of 25 mg/kg/day was tolerated. At postmortem examination, dorsal
root ganglia at each spinal level were dissected microscopically. Median tumor size was not
reduced in response to any of the three experimental drugs (Fig 5B). Further, histologic exami-
nation of DRGs from both control and drug treated PostnCre; Nf2floxflox mice had comparable
disrupted architecture consistent with schwannoma irrespective of treatment (Fig 5D). Finally,
there was a progressive decline in hearing threshold as measured by ABR regardless of drug
used (Fig 5C).
Molecular characterization of untreated and treated cell lines
A major goal of this work was to investigate the outcomes of traditional drug screening of can-
didate drugs for tumor toxicity based on phenotype sequentially in vitro and in vivo as well as
to explore the potential for drug discovery driven by molecular and protein characterization
via global gene expression and kinome analysis. We hypothesized that the latter might reveal
molecular differences that could point to specific therapeutic targets not previously apparent
with toxicity specific to merlin-deficient cells. Accordingly, the most reliable and reproducible
lines from the meningioma and schwannoma assay systems were selected for transcriptome
Systems based drug discovery for NF2
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and kinome analysis. The seven meningioma-relevant and schwannoma-relevant cell lines
were treated for 24 hours either with DMSO alone or with the doses of GSK2126458, Panobi-
nostat, CUDC-907 chosen as described in Materials and Methods (S5 Text) and harvested for
transcriptome and kinome analyses.
Transcriptome analysis of meningioma and schwannoma cell systems
To assess the effects of merlin deficiency on global gene expression in the seven test cell lines,
we performed RNA sequencing (RNAseq). Principal components analysis (PCA) of rank-nor-
malized gene counts indicated that the three models (human AC/MN cells, human SC, and
mouse SC) showed substantial transcriptional differences between species and tumor type (Fig
6A); concordant with the response of the cells to the drug panel tested (Fig 3, S3 Table). Direct
comparison of the merlin-deficient cells with their merlin-expressing counterparts revealed
extensive changes in gene expression (Figs 6B and 6C, S4 and S5 Tables, S3 Text).
Pathway analysis of gene ontology (GO) terms [48] with the Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) [49,50] showed that the human differentially
expressed genes point strongly to significant alterations in the extracellular region, plasma
membrane and adhesion of both merlin-deficient AC and SC (S6 Table). Some GO terms
(such as GO:0005886~plasma membrane, GO:0005887~integral component of plasma
Fig 5. In vivo testing in schwannoma. Nf2 flox/flox; Postn cre+ mice were treated for 12 weeks at the maximum
tolerated dose, beginning at 6 months of age. (A) Pharmacokinetics of GSK2126458, Panobinostat and CUDC-907 in
PostnCre; Nf2floxflox mice. Dosage is reported in (a) PO mg/kg/day, (b) IP mg/kg 3x/week. Cmax is reported in ng/ml.
AUC reported as ng/ml/h. t1/2 reported in hours. Cl/F reported as L/Hr. Vdss/F reported as L. Cmax tissue reported as
ng/g of tissue. (B) Dorsal root ganglion (DRG) size was measured by dial caliper; each data point represents one
individual DRG location. Four individual DRG locations were measured per mouse; (C) ABR threshold was measured
before and after 12 weeks treatment. ABR threshold was significantly increased after 12 weeks with treatment
(p>0.0001) by one-way ANOVA. (D) Paraffin-embedded slides of DRG from treatment mice were stained with
hematoxylin and eosin (H&E).
https://doi.org/10.1371/journal.pone.0197350.g005
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membrane, GO:0005615~extracellular space, GO:0005576~extracellular region, and
GO:0016021~integral component of membrane) were significantly enriched among both
downregulated and upregulated genes in the AC comparison. The same five terms were the
most significant among the downregulated genes in human SC, and three of the five were also
significant among the upregulated human SC genes. Despite this apparent overlap in the pro-
cesses disrupted by merlin loss in the two cell types, the actual differentially expressed genes in
the two cell systems were largely distinct, with only 240 (21.7%) of the 1,107 differentially
expressed genes in the human SC system also being differentially expressed in the human AC
system. Off these, only 154 (13.9%) were altered in the same direction (80 down and 74 up)
(Fig 6, S7 Table). Similarly, despite the lack of overlap noted above between differentially
expressed genes in mouse SC compared to human SC, the mouse differentially expressed
genes point to many of the same GO terms as being enriched (S6 Table). The relative lack of
correspondence of the actual differentially expressed genes yet enrichment overall of differen-
tially expressed genes for similar GO terms is consistent with loss of merlin function operating
in similar processes within the distinct biology of the different target cell types.
A comparison with the druggable genome indicates that many of the differentially
expressed genes might be expected to confer differential response or sensitivity of merlin-defi-
cient and wild-type human cells. Of the 1,969 and 1,107 genes differentially expressed due to
merlin loss in the human AC and SC comparisons, 343 and 236, respectively, are considered
“druggable” based upon the Drug Gene Interaction database (http://dgidb.genome.wustl.edu/)
(S8 Table) and many of these are associated with known drugs. For example, as a result of mer-
lin loss, AC overexpress mRNA for the tyrosine kinase EPHA2, which is sensitive to Dasatinib
[51], whereas SC overexpress EPHA5 transcripts. Both the AC and SC overexpress KIT,
Fig 6. PCA and transcriptomic differences due to merlin deficiency in human AC and SC. (A) Principal components analysis (PCA) of averaged, rank-
normalized read counts (overlapping genes only) from RNA-seq of wild type and merlin-deficient human SC (red), mouse SC (orange), human AC (blue, Syn5,
Syn1) and human MN cells (blue, Syn6). PC1 explains 61.5% of variance, while PC2 explains 25.5% of variance. (B) Volcano plots showing the significance and
log2 fold-change (logFC) due to merlin deficiency for all gene transcripts reliably detected in the RNA-seq analysis. Yellow dots represent genes altered at [47]
adjusted significance of P<0.05. The location of the downregulated NF2 gene, corresponding with ~7% of normal NF2 expression, is labelled for HS01 vs HS11. In
the Syn5 vs Syn1 AC comparison, fold-comparisons across the entire gene are not meaningful as there is no significant difference in the level of NF2 transcripts in
Syn5, but these produce no active merlin due to absence of exon 8 (S5 Fig), which was removed by CRISPR/Cas9. (C) Venn diagrams showing the relatively small
degree of overlap between the downregulated (left) and upregulated genes (right) due to merlin deficiency in human AC and SC, respectively.
https://doi.org/10.1371/journal.pone.0197350.g006
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encoding the KIT proto-oncogene receptor tyrosine kinase, which is inhibited by Sunitinib
[52,53], among many other compounds. Beyond these and several other kinases, there are
many other categories of druggable genes whose mRNAs are either over- or under-expressed
in merlin-deficient AC and/or SC. Notably in AC, the matrix metallopeptidases, MMP1,
MMP2 and MMP10 and the ion channels, CACNA1A and TRPV2, and in SC, the G protein-
coupled receptors GPR37 and NTSR1, are among the genes most highly upregulated by loss of
merlin. Several other categories of potentially “druggable” genes, including transporters,
growth factors, proteases, lipases, phosphatases, cell surface proteins, histone modifiers and
transcription factors are also represented and provide a variety of potential routes to differen-
tial perturbation of wild-type and merlin-deficient human AC and/or SC.
Transcriptome analysis of drug-treated arachnoidal/meningioma and
Schwann cells
Despite these substantial differences between the transcriptomes of merlin-deficient and mer-
lin-wildtype cells, the three drugs that were chosen from our cellular screening for further test-
ing produced no significant differential effect in our cell viability assays, suggesting that they
do not target processes that are preferentially important to viability of merlin-deficient cells.
However, they did elicit extensive changes in gene expression in the human cell lines (S4 and
S5A Tables, S6A Fig), with some hints of differential response that reflect biological differences
due to merlin loss (S4 Text; S9 Table).
Kinome analysis of untreated cells
To understand dynamic changes in the functional kinome, we employed multiplexed Type I
kinase inhibitor bead (MIB)/mass spectrometry (MS) kinome profiling. MIBs have preferential
affinity for the activated form of kinases, and MIB-binding is dependent on affinity, expres-
sion, and activation state of the kinase [54,55]. Gravity-flow captured kinases are eluted and
identified by MS. Analyzing isogenic cell lines that differ by a single mutation or comparing
samples before and after drug treatment provide a global view of changes in the kinome activa-
tion state due to genotype or drug perturbation.
A comparison of the MIB/MS kinome profiles of merlin wild-type and deficient cells identi-
fied several differentially expressed and activated kinases associated with loss of merlin (Fig 7).
Among these, merlin-deficient Syn5 AC showed increased MIB binding of receptor tyrosine
kinases such as EPH receptor proteins B1 and A4, KIT, and FLT1/VEGFR1, and RPS6KB1/
p70S6K as compared to the isogenic merlin-wildtype Syn1 cells. Merlin-dependent differences
were also detected in the human SC kinome; the merlin-suppressed HS01 SC line had
increased binding of EPH receptor EPHA3, and the Unc51-like kinase ULK4, a serine-threo-
nine kinase with likely function in neuronal growth and migration, and cortex growth [56].
Overall, the baseline data for human meningioma- and schwannoma- relevant isogenic pairs
indicate both similarities and differences between these two disease models. Loss of merlin in
both cell types results in increased EPH receptor pathway kinases[57], but several non-overlap-
ping kinases associated with merlin-deficient cells were also observed (Fig 7A and 7B). These
findings suggest that although some therapeutic approaches may target both meningioma and
schwannoma, tumor-type specific targets should also be explored.
In addition to human models, MIB/MS kinome profiles were obtained for a single run of
the merlin-deficient (MS03) and merlin-wildtype (MS12) mouse SC lines (S7 Fig). Consistent
with the human kinome data, merlin-deficient cells (MS03) displayed increased MIB binding
of EPH receptor kinases (EPHB6, EPHA2) as compared to merlin-wildtype mouse SC (MS12).
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Fig 7. Kinome changes across human isogenic merlin-wildtype and -deficient AC and SC pairs. (A-B) Top baseline
kinome changes across human AC and SC isogenic pairs. Data presented are the mean log2 fold change from 3
experiments, error bars are standard error. (C) Pan-kinome (left) drug induced perturbations relative to DMSO
control contain clusters of induced/repressed kinases (right). Each condition is the median log 2 fold change of three
replicate experiments relative to vehicle (DMSO) control, with any kinase having>33% non-detection rate removed
(grey: kinase not detected in any run). Cell lines treated with HDAC inhibitors (Panobinostat and CUDC-907) cluster
most closely.
https://doi.org/10.1371/journal.pone.0197350.g007
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Kinome analysis of drug treated cells
We next compared perturbations to the kinome in the meningioma and schwannoma cell sys-
tems after treatment with CUDC-907, GSK2126458, Panobinostat, or vehicle. To analyze the
effect of all three drugs on the kinome of all three cell line pairs, we also queried a protein
interaction database (string-db.org) for potential subnetworks that were selectively induced in
the merlin-deficient cell lines.
Initially, we surveyed the drug-specific responses observed by kinome profiling, irrespective
of merlin status. Consistent with the growth inhibition observed with the selected compounds,
numerous CDKs and mitotic kinases (CDK1, CDK2, AURKA, PKMYT1, PLK1) exhibited
dramatic MIB binding loss in all cell lines tested (Fig 8). Dual inhibition of PI3K/mTOR by
GSK2126458 led to a strong increase in MIB binding of INSR and IGF1R, which has been pre-
viously described in response to mTOR inhibition [58]. Treatment with Panobinostat or
CUDC-907 both led to increased MIB binding of PTK2B (FAK2), RPS6KA1 (p90RSK) and
the EPH receptors EPHA4 and EPHB2. The shared response between Panobinostat and
CUDC-907 could reflect HDAC inhibitor-dependent adaptive changes (Fig 7C) and further
suggests that the use of an inhibitor of FAK, RSK, or EPHA4/B2 in combination with Panobi-
nostat and CUDC-907 may be more effective in eradicating merlin-deficient tumors.
Following our assessment of the predominant drug-specific kinome responses, we exam-
ined the specific kinome response in the merlin-deficient AC and SC (S8 Fig) versus their mer-
lin-wild-type counterparts. In the meningioma model (Syn5 and Syn1), all three drugs
induced merlin-deficient-specific kinase networks that included MAPK proteins, PTK2
(FAK1) and ephrin receptor proteins among other kinases. In the human schwannoma model
(HS01 and HS11), PTK2 and PTK2B (FAK1 and FAK2) were induced by all three drugs in a
merlin-deficient-specific manner. In addition, both HDAC inhibitors selectively induced
mTOR-centered kinase subnetworks in merlin-deficient human SC. We also observed merlin-
dependent induced differential kinome perturbation in the mouse schwannoma model (MS03
and MS12). Similar to human schwannoma and meningioma, CUDC-907, GSK2126458 and
Panobinostat also selectively induced MAP kinases, ephrin receptor kinases, and PTK2, sug-
gesting that the mouse model recapitulates elements of the human tumor cell response to these
drugs.
Overall, HDAC inhibitors generated the largest fold-changes in MIB-binding and at 24
hours clustered separately from GSK458-mediated responses (Fig 7C). The HDAC inhibitors
induced a series of tyrosine kinases (TKs) consistently across cell lines, including PTK2,
PTK2B, JAK1, FYN, EPHA4, EPHB2, and EPHB1 (Fig 8A).
As several nodes common to the human merlin-deficient models and the three drugs tested
were identified, it is possible that cells lacking merlin have a similar kinomic response to treat-
ment with these three drugs. Shown in a kinome tree plot, similarities between CUDC-
907-induced and Panobinostat-induced changes were evident (induced changes in Syn5, Fig
8B). Kinases that were represented in every cell line were used to generate a MIB-binding
response correlation matrix (Fig 8C–8E). Two of the most-prominent clusters included
kinases highly-correlated with PTK2 (FAK1) or RPS6KA1 (p90RSK) and STK3/4. The most-
highly correlated kinases were INSR and IGF1R (corr = 0.91), primarily being induced by
GSK2126458-treatment at 24 hours (Fig 8F). The next-most correlated kinase pair across the
entire dataset was PTK2 and AAK1 (corr = 0.87) (Fig 8G). Interestingly, these kinases were
preferentially induced in merlin-deficient cell lines.
To further corroborate the findings from the kinome analysis, Western blot experiments
were performed. Merlin-deficient human SC compared to isogenic wild-type human SC have
an increased basal level of PTK2B (FAK2). In response to treatment with GSK2126458,
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CUDC-907 and Panobinostat, both human and mouse merlin-deficient SC cells had increased
PTK2B levels when compared to wild-type control cells (S9 Fig). The differential response of
PTK2B levels in both merlin negative human and mouse SCs might indicate a potential target
for combination therapy. Like the cellular kinome analysis, meningioma xenografts treated
with these drugs showed increased levels of pFAK (S4E Fig), suggesting similar responses in
vitro and in vivo.
Integrated kinome-transcriptome analysis of untreated and drug treated
cells
To assess the relationship between transcriptome and kinome changes, we performed an inte-
grated analysis of these two datasets at baseline and after CUDC-907, Panobinostat and
GSK2126458 treatment of the meningioma- and schwannoma-relevant cell models. In particu-
lar, we focused on a comparison between merlin-deficient cells and merlin-wildtype cells for
kinases showing a log2 difference of greater than 0.5 or less than -0.5 in the kinome, and/or
greater than 1 or less than -1 in the transcriptome (labeled in Fig 9). AC lines without merlin
(Syn5 vs Syn1) at baseline showed upregulation of the kinases EPHA4, EPHB1 and KIT in
both the kinome and transcriptome. By contrast, in the SC (HS01 vs. HS11), no kinase met the
threshold criteria above for having been upregulated in both the kinome and transcriptome
(Fig 9, left). No kinases showed downregulation by merlin deficiency in either kinome or tran-
scriptome at these thresholds in either AC or SC, but AURKA showed decreased activity
(<-0.5 logFC) due to merlin-deficiency in both cell types without exceeding the threshold dif-
ference in the transcriptome. A number of kinases did not show corresponding differences in
their activity and transcript levels, such ULK4 in AC which exhibited increased activity with-
out a change in mRNA and PTK2B and MET which were decreased in the transcriptome data
(<-1 logFC) but mildly increased in the SC kinome by merlin deficiency.
We also studied the correlation of merlin-dependent changes in the kinome and transcrip-
tome of AC and SC due to drug treatment (Fig 9, right). Unlike the baseline comparison, this
analysis was not aimed at whether individual kinase activities or transcript levels increased or
decreased per se (as presented for merlin-deficient cells in S5 Table, and S6 and S8 Figs).
Rather, we assessed relative quantitative differences between the kinome and transcriptome
responses of merlin-deficient and merlin-wild-type cells to these drugs. A comparison of fold-
changes in these measures in the isogenic pairs reinforced the difference in response of AC
and SC to these drugs and the fact that differences in kinase activity often occur in the absence
of comparable differences in expression of the kinase-encoding gene. The most striking exam-
ple of the latter is EPHB1 in CUDC-907 treated AC, where absence of merlin resulted in rela-
tively higher kinase activity (>0.5 LogFC) but relatively lower EPHB1 gene expression (<-1
LogFC) in Syn5 compared to Syn1. A number of kinases displayed relatively higher activity in
the absence of relative differences beyond the threshold for mRNA levels (e.g., AURKA in
both Panobinostat and GSK2126458 treated SC). Overall, the integrated analysis suggests that
the kinome and transcriptome measures provide somewhat different windows on the response
of cells to drug treatment and that both together and separately, they can reveal cell type and
Fig 8. Kinomic response to drug treatment. (A) Ranking the top 10 most-induced and most-suppressed kinases for each of the treatments at 24 hours stresses the
similarities in drug response across cell lines, and also the differences between human and mouse cell lines. (B) Drug induced perturbations in HS-01 and Syn5
shown in a kinome tree plot. (C) Kinases that were represented in every cell line were used to generate a MIB-binding response correlation matrix. (D-E) Two of
the most-prominent clusters include kinases highly-correlated with PTK2 (FAK1) or RPS6KA1 (p90 RSK) and STK3/4. (F) The most-highly correlated kinases are
INSR and IGF1R (corr = 0.91), primarily being induced by GSK458-treatment at 24 hours. (G) The next-most correlated kinase pair across the entire dataset is
PTK2 and AAK1 (corr = 0.87). Interestingly, these kinases are preferentially induced in merlin-deficient cell lines.
https://doi.org/10.1371/journal.pone.0197350.g008
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genotype (merlin status) differences that can provide additional targets for single or combina-
tion drug treatment.
Discussion
Schwannomas and meningiomas are the most common brain tumors in humans world-wide
[3] and despite years of efforts, there are no effective drug therapies for these tumors. In the
setting of NF2, the number and distribution of these tumors results in cumulative morbidity
and ultimately mortality that cannot be successfully managed with surgery or radiotherapy. As
a result, there is a desperate need for new therapeutics for NF2 associated tumors. A partial
explanation for the difficulty in identifying effective therapies for NF2 associated schwanno-
mas and meningiomas is the difficulty in creating assay systems given that these are benign,
slow growing tumors with relatively bland mutational backgrounds. Moreover, unlike the
search for highly cytotoxic compounds aimed at killing aggressive, malignant tumors, NF2
patients require drugs that are well tolerated for long intervals of treatment and inhibit mutant
but not normal cells. To address these challenges, this vertically integrated project used cul-
tured Schwann cells (SC) and arachnoidal cells (AC), in some cases genetically manipulated to
inactivate or suppress merlin expression, to create a comprehensive cell assay system repre-
senting both schwannoma and meningioma. The hope was that a single agent would have
activity based on merlin status across tumor types making it clinically feasible for patients to
take one agent to address both their NF2 driven schwannomas and meningiomas. However,
despite priming the pipeline with 19 drugs chosen for potential relevance to NF2 biology, we
observed relatively little difference overall in the sensitivity of merlin-wildtype cells compared
with merlin-deficient cells. Instead, the strongest influences on drug efficacy were cell type
(AC vs. SC), followed by species of origin (human vs. mouse).
These are important findings that would not have been possible without assembling a
robust, isogenically matched panel of cell lines for the tumors and mutation of interest. The
Fig 9. Integrative analysis of kinome and transcriptome data at baseline (left) and after drug treatment (right) with CUDC-907, Panobinostat, or GSK2126458.
In comparisons at baseline or after drug treatment. Kinases are plotted as black dots based upon the log2 fold difference (logFC) in their activity and transcript level
between similarly treated merlin-deficient and merlin-wildtype human isogenic cell pairs, Syn5 vs. Syn1 for AC and HS01 vs. HS11 for SC. Kinases showing a
difference of logFC<-0.5 or> 0.5 in kinase activity and/or logFC<-1 or>1 in transcript level are labelled and colored based upon the color code scheme to the right
of the graphs (e.g., relatively greater in merlin-deficient cells compared to merlin-wildtype cells than the stated thresholds in both kinase activity and transcriptome
data = dark red; relatively greater only in kinase activity = light red, etc.).
https://doi.org/10.1371/journal.pone.0197350.g009
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lack of differential drug activity relative to merlin status underscores the inherent difficulty of
choosing candidates for testing based upon phenotypic measures alone. While tumor forma-
tion is initiated by loss of merlin, many of the consequent characteristics and altered pathways
observed in tumors and tumor cells may not be essential for their propagation and therefore
may not be useful targets for genotype-specific therapeutic development. An assessment of
such features is particularly difficult in primary tumor specimens where a truly comparable
normal tissue sample is usually lacking. By establishing a cell-based system with genetically-
matched merlin-expressing and merlin-deficient cells representing the cellular targets of the
two major tumor types in NF2 patients, we provide the capacity to go beyond the phenotypic
candidate approach to strategies informed by genotype-dependent systems analyses or to
larger, mechanism-agnostic drug screens.
The cell type and species differences seen in the drug screen were reinforced with the tran-
scriptome and kinome analyses of isogenic pairs of merlin-deficient and merlin-wildtype cells.
In the transcriptome studies, the absence of merlin resulted in global differences in gene
expression in SC and AC versus their wild-type counterparts. In both human and mouse SC
pairs and in the human AC pair, the gene expression changes indicated that loss of merlin
function disrupts processes related to the plasma membrane and extracellular region/space.
However, the actual genes dysregulated were largely non-overlapping, suggesting that the loss
of functional merlin affects shared processes in different ways, in different cell types. This is an
important, yet subtle, discovery that will inform drug development strategy for NF2 driven
tumors.
Principal components analysis of the global gene expression data emphasized that cell type
and species differences outweigh the effects of merlin deficiency. Similarly, kinome analysis
revealed the activation of different kinases in human AC compared to human SC. Taken
together, these data suggest that while schwannomas and meningiomas are both initiated by
merlin loss, distinctly different responses to that loss likely dictate tumor propagation. Clini-
cally, this means that a single drug is unlikely to be optimally effective in both cell types. Fur-
ther, when selecting a drug for one tumor type, caution will be required about potential
transcriptome and kinome effects on the other tumor type.
In the absence of strong selective toxicity to merlin deficient cells for the 19 drugs tested, we
chose three, CUDC-907 (dual PI3K/HDAC inhibitor), Panobinostat (HDAC inhibitor), and
GSK2126458 (dual PI3K/mTOR inhibitor) for in vivo testing based on traditional markers of
activity in vitro across all cell lines. We saw activity, notably for GSK2126458 and Panobino-
stat, in the meningioma in vivo model, but none of the three agents was active in vivo in the
GEM schwannoma model. The difference in vitro versus in vivo activity for schwannoma may
be due to contributions from the microenvironment that are not addressed in either the in
vitro schwannoma systems or in the allograft meningioma system [59]. It also highlights that
the cell-type specific 2D culture system cannot completely reflect either the vulnerabilities or
resistances of the corresponding tumor in vivo. The lack of strong selective toxicity against
merlin-deficient cells with the initial 19 drug candidates screened likely indicates that they all
target processes whose role in determining viability in vitro is not dependent on merlin,
although it cannot be excluded that a role for merlin activity in determining viability in a sys-
tem more faithful to the 3D in vivo environment might reveal selectivity for one or more of
these compounds.
Developing advanced assays and screening a much larger panel of chemical compounds are
two potential approaches to achieving selective toxicity for the merlin-deficient tumor cells
while sparing their wild-type counterparts. Indeed, we would have altered the drug panel
screened if had baseline transcriptome and kinome data before starting the drug screen. For
example, the emergence of increased activity of ephrin receptor kinases in merlin-deficient
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cells would have prompted the addition of Dasatinib to the screen and increased CAMK4 in
human merlin-deficient SC would have suggest the drug KN-93 [53,60]. In fact, based on the
observed changes in kinome in NF2-null human AC and MN cell lines in this study a thera-
peutic trial was undertaken in vitro and in vivo that indeed showed synergy between dasatinib
and a dual mTORC inhibitor that was predicted by kinome results[61]. There are many other
options available both among kinases and other known druggable targets. Hence, using the
cell lines characterized in this work, efforts are ongoing for more drug screening with more
comprehensive drug libraries.
Perhaps the most important outcome of this work was the validation of diverse cell lines
with isogenic pairs allowing the generation of transcriptome and kinome data at baseline and
in response to drug. This is a rich data source to mine to identify combination therapies that
influence transcriptome or kinome; potentially engaging merlin deficiency in determining via-
bility. Combination therapy guided by such molecular data may reveal circumstances in which
response to a single agent in merlin-deficient cells creates a vulnerability to be exploited by a
second agent, achieving selective toxicity. Future work may use the differences between mer-
lin-wildtype and merlin-deficient cells in their molecular response to CUDC-907, Panobino-
stat, and GSK2126458, to identify potential agents that will be additive or synergistic. For
example, the AMP-activated protein kinase NUAK1 (inhibitor: WZ4003) [62] was selectively
upregulated in merlin-deficient schwannoma cells by GSK2126458. PTK2B (inhibitor: defacti-
nib) [63] was upregulated in merlin-deficient schwannoma cells by Panobinostat and AURKA
(inhibitor: alisertib) [64] was upregulated in merlin-deficient meningioma upon treatment
with GSK2126458 and CUDC-907. Expanding the list of those datasets available to isogenic
pairs treated with drugs suggested by the baseline transcriptome and kinome data may provide
yet more attractive combinations based upon the emerging biology of merlin-deficiency in
these cell types.
The ongoing efforts of the Synodos for NF2 Consortium have already filled a critical gap of
understanding of how the NF2 mutation and the absence of merlin influence tumor cell behav-
iour in both meningiomas and schwannomas and succeeded in: (1) creating a new pipeline of
well-validated cell lines for NF2-associated drug discovery with fully characterized isogenic
pairs of meningioma and schwannoma cell systems; (2) gaining conceptual insights into dis-
ease mechanisms via transcriptome and kinome interrogation that indicate that different
drugs are likely to be needed to treat meningioma and schwannoma; (3) validating pathways
and targets that are altered based on tumor type (more so than mutational status) and in
response to targeted pathway inhibition in the setting of NF2; and 4) building an openly acces-
sible (www.synapse.org/SynodosNF2) database for community sharing and mining of drug
treatment, transcriptome and kinome data from isogenic schwannoma and meningioma cell
systems. These data already present several targets to consider for single agent and combina-
tion therapy in the short term and provide a deep and rich open access data resource for the
broader research community seeking treatments for NF2 associated meningioma and schwan-
noma for the long term.
Materials and methods
Detailed materials and methods can be found in S5 Text.
Supporting information
S1 Table. Response measurements in AC and MN lines of compounds not meeting efficacy
metrics.
(XLSX)
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S2 Table. Response measurements in human and mouse SC/schwannoma lines of com-
pounds not meeting efficacy metrics.
(XLSX)
S3 Table. Drug screening outcomes are largely independent of merlin status. Multiple lin-
ear modeling was used to test the association of each assay variable with differences in area
under the curve (Simpson AUC). This table shows the effect of each variable on the AUC as
determined by the model (the beta coefficient, B), the 95% confidence interval (CI) for the beta
coefficient, and calculated significance (p) for the beta coefficient. Only drugs common to
both cell types were included in the analysis. The fraction of observations that are explained by
the model (R2) and the total number of data points in the model (Observations) are also
shown.
(XLSX)
S4 Table. Number of differentially expressed genes in merlin-wildtype and merlin–defi-
cient cell lines at baseline and in response to drug treatments.
(XLSX)
S5 Table. Transcriptomic differences in isogenic pairs of untreated and drug-treated merlin
-deficient and merlin-wildtype human arachnoidal cells and Schwann cells (A) and mouse
Schwann cells (B)
(XLSX)
S6 Table. Gene Ontology (GO) Terms significantly enriched among differentially
expressed genes due to merlin deficiency.
(XLSX)
S7 Table. Genes differentially expressed due to merlin deficiency in both human arachnoi-
dal cells and Schwann cells.
(XLSX)
S8 Table. Representation in the druggable genome of human genes differentially expressed
due to merlin deficiency in human arachnoidal cells and Schwann cells.
(XLSX)
S9 Table. Differentially expressed genes due to drug treatment of isogenic human merlin-
wildtype and merlin-deficient arachnoidal cell and Schwann cell pairs that are discordant
for direction of response.
(XLSX)
S1 Fig. Characterization of screening cell lines. (A) Immunoblotting of isogenic immortal-
ized AC-CRISPR clones (iACs) using the N-terminal anti-MERM antibody N21 (raised to a
common epitope shared between merlin and other ERM protein family members) shows loss
of merlin in Syn3-5 compared to merlin-wildtype Syn2, with intact expression of other ERM
family members. (B) Immunoblotting of representative panels of iACs (AC-CRISPR clones
Syn1-5), immortalized MN (iMN, Syn6), and primary MN cell lines (Syn7, Syn10, Syn12)
show merlin-deficient (-) compared to merlin-wildtype (+) Syn1 and Syn2 lines. Loading con-
trols included housekeeping proteins ribosomal S6 subunit (left and center panel) and
GAPDH (right panel). (C) Representative merlin Western blots of whole cell extracts from pri-
mary mouse Schwann cells MS11 (WT) and merlin-deficient (MD; Nf2ex2-/-) MS01, MS02
lines, isogenic MS12 (WT) and MS03 (MD), and isogenic HS11 (WT) and HS01 (MD). β-
actin was immunoblotted as a loading control. (D) Confocal images of mouse Schwann
Systems based drug discovery for NF2
PLOS ONE | https://doi.org/10.1371/journal.pone.0197350 June 13, 2018 19 / 26
/schwannoma cell lines MS11, MS01, MS02, MS12 and MS03 showing the SC marker S-100
(green). Human Schwann cell lines HS11 and HS01 displaying S-100 (green) and human
nuclear antigen (HNA, red). DAPI stained nuclear DNA (blue), and F-actin (phalloidin-
Alexa633; white) is also shown. Scale bar: 50 μm.
(TIF)
S2 Fig. Treatment response of human merlin-wildtype and merlin-deficient cells with
compounds failing to meet efficacy metrics. (A) Human arachnoidal and meningioma cells.
CellTiter-Glo was assessed at 72 hours of drug treatment (B) Human Schwann cells. CellTiter-
Fluor was assessed at 48 hours of drug treatment with increasing concentration at half-log con-
centrations, ranging from 0.001 μM to 10 μM.
(TIF)
S3 Fig. Treatment response of mouse merlin-wildtype and merlin-deficient cells with com-
pounds failing to meet efficacy metrics. CellTiter-Fluor was assessed at 48 hours of drug
treatment with increasing concentration at half-log concentrations, ranging from 0.001 μM to
10 μM.
(TIF)
S4 Fig. Immunohistochemistry confirmation of target engagement in Ben-Men1 (Syn6)
tumors. (A) Acetylated histone lysine was evaluated in Syn6 tumors as a readout of HDAC
inhibition. (B) pAKT(Thr308 and Ser473) and pS6(S235/236) reduction demonstrate AKT
pathway inhibition in Syn6 tumors after treatment with all three drugs. (C) pS6(S235/236) and
(D) Ki67 was reduced in Syn6 tumors after treatment with GSK2126458, Panobinostat, and
CUDC-907, while (E) pFAK (Tyr397) was increased.
(TIF)
S5 Fig. Integrated genomics viewer comparison of NF2 transcripts from RNAseq in Syn5
and MS03. (A) Plotting of transcript reads against the exon structure of NF2 demonstrates the
complete skipping of the CRISPR/Cas9-targeted exon 8 and presence of a novel antisense
RNA in Syn5 compared with Syn1. (B) Nf2 transcripts show complete skipping of exon 2, a
floxed exon removed by Cre recombinase, in MS03 compared with MS12.
(TIF)
S6 Fig. Transcriptome response of merlin-deficient human cells to drug treatments. (A)
Volcano plots showing the significance and log2 fold-change (logFC) for all gene transcripts
reliably detected in the RNA-seq analysis after treatment of Syn5 or HS01 with the noted drug,
in comparison with exposure to the DMSO vehicle. Yellow dots represent genes altered at BH
adjusted significance P<0.05.
(B) Venn diagrams showing the overlap between the genes downregulated (left) and upregu-
lated (right) due to the above drug treatments.
(TIF)
S7 Fig. LFQ kinome measurements of mouse schwannoma cell line MS03 versus MS12
(single run).
(TIF)
S8 Fig. Kinome changes in human merlin-deficient arachnoidal cells and Schwann cells.
Top kinome changes in merlin deficient human AC (Syn5) and SC (HS01) treated with
CUDC-907, Panobinostat or GSK2126458. Data presented are the median log2 fold change
from 3 experiments, error bars are standard error.
(TIF)
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S9 Fig. PYK2 differential response to drug treatment. Both merlin-deficient mouse and
human Schwann cells (SCs) increase PYK2 levels in response to DMSO, CUDC-907, Panobi-
nostat and GSK2126458. Immunoblot analysis of human (HS11 and HS01) (A) and mouse
(MS12 and MS03) (B) merlin-deficient SCs compared to wild-type control. Membranes were
treated with merlin and PYK2 antibodies as indicated. 25 μg of lysates were used and equal
loading was controlled by Ponceau S staining. These immunoblots are representative of three
independent experiments.
(TIF)
S1 Text. In vivo testing of candidate compounds in a meningioma xenograft model–immu-
nohistochemical analysis.
(DOCX)
S2 Text. Translation of in vitro to in vivo efficacy studies in meningioma and schwannoma
models.
(DOCX)
S3 Text. Transcriptome analysis of meningioma and schwannoma cell systems–differential
gene expression.
(DOCX)
S4 Text. Transcriptome analysis of drug-treated arachnoidal/meningioma and Schwann
cells.
(DOCX)
S5 Text. Materials and methods.
(DOCX)
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